The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)

K. M. Wasan, P. E. Goss, P. H. Pritchard, L. Shepherd, M. J. Palmer, S. Liu, D. Tu, J. N. Ingle, M. Heath, D. DeAngelis, E. A. Perez

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Background: The purpose of this study was to evaluate changes in serum lipid parameters {cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein(a) [Lp(a)]}, in postmenopausal women receiving letrozole or placebo after adjuvant tamoxifen for early stage breast cancer (NCIC CTG MA.17L). Patients and methods: MA.17L is a substudy of MA.17, a randomized, double-blind, placebo-controlled trial of letrozole 2.5 mg taken daily for 5 years in postmenopausal women with primary breast cancer completing ∼5 years of prior adjuvant tamoxifen. Patients consenting to participate in this companion study had blood drawn and lipid parameters (total cholesterol, HDL cholesterol, LDL cholesterol, Lp(a), triglycerides) evaluated at baseline, 6 months, 12 months and yearly thereafter until completion of protocol therapy. It was required that women be non-hyperlipidemic and not taking lipid-lowering drugs at time of entry on this trial. Results: Three hundred and forty seven women were enrolled in the study. The letrozole and the placebo groups demonstrated marginally significant differences in the percentage change from baseline in HDL cholesterol at 6 months (P = 0.049), in LDL cholesterol at 12 months (P = 0.033) and triglycerides at 24 months (P = 0.036). All comparisons of lipid parameters at other time points were not significantly different between the two treatment groups. No statistically significant differences in the number of patients exceeding the thresholds defined for the lipid parameters were found between the two treatment groups. Conclusions: The MA.17 trial demonstrated a significant improvement in disease-free survival with the use of letrozole as extended adjuvant therapy post tamoxifen. Results from this study suggests that letrozole does not significantly alter serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides or Lp(a) in non-hyperlidiemic postmenopausal women with primary breast cancer treated up to 36 months following at least 5 years of adjuvant tamoxifen therapy. These findings further support the tolerability of extended adjuvant letrozole in postmenopausal women following standard tamoxifen therapy.

Original languageEnglish (US)
Pages (from-to)707-715
Number of pages9
JournalAnnals of Oncology
Volume16
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

letrozole
Tamoxifen
Breast Neoplasms
Lipids
LDL Cholesterol
HDL Cholesterol
Lipoprotein(a)
Serum
Cholesterol
Placebos
Triglycerides
Therapeutics
Disease-Free Survival

Keywords

  • Letrozole
  • Postmenopausal women
  • Primary breast cancer
  • Serum lipids
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). / Wasan, K. M.; Goss, P. E.; Pritchard, P. H.; Shepherd, L.; Palmer, M. J.; Liu, S.; Tu, D.; Ingle, J. N.; Heath, M.; DeAngelis, D.; Perez, E. A.

In: Annals of Oncology, Vol. 16, No. 5, 05.2005, p. 707-715.

Research output: Contribution to journalArticle

Wasan, KM, Goss, PE, Pritchard, PH, Shepherd, L, Palmer, MJ, Liu, S, Tu, D, Ingle, JN, Heath, M, DeAngelis, D & Perez, EA 2005, 'The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)', Annals of Oncology, vol. 16, no. 5, pp. 707-715. https://doi.org/10.1093/annonc/mdi158
Wasan, K. M. ; Goss, P. E. ; Pritchard, P. H. ; Shepherd, L. ; Palmer, M. J. ; Liu, S. ; Tu, D. ; Ingle, J. N. ; Heath, M. ; DeAngelis, D. ; Perez, E. A. / The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). In: Annals of Oncology. 2005 ; Vol. 16, No. 5. pp. 707-715.
@article{1a3c02fbe0ea40dbafddec2116098fc7,
title = "The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)",
abstract = "Background: The purpose of this study was to evaluate changes in serum lipid parameters {cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein(a) [Lp(a)]}, in postmenopausal women receiving letrozole or placebo after adjuvant tamoxifen for early stage breast cancer (NCIC CTG MA.17L). Patients and methods: MA.17L is a substudy of MA.17, a randomized, double-blind, placebo-controlled trial of letrozole 2.5 mg taken daily for 5 years in postmenopausal women with primary breast cancer completing ∼5 years of prior adjuvant tamoxifen. Patients consenting to participate in this companion study had blood drawn and lipid parameters (total cholesterol, HDL cholesterol, LDL cholesterol, Lp(a), triglycerides) evaluated at baseline, 6 months, 12 months and yearly thereafter until completion of protocol therapy. It was required that women be non-hyperlipidemic and not taking lipid-lowering drugs at time of entry on this trial. Results: Three hundred and forty seven women were enrolled in the study. The letrozole and the placebo groups demonstrated marginally significant differences in the percentage change from baseline in HDL cholesterol at 6 months (P = 0.049), in LDL cholesterol at 12 months (P = 0.033) and triglycerides at 24 months (P = 0.036). All comparisons of lipid parameters at other time points were not significantly different between the two treatment groups. No statistically significant differences in the number of patients exceeding the thresholds defined for the lipid parameters were found between the two treatment groups. Conclusions: The MA.17 trial demonstrated a significant improvement in disease-free survival with the use of letrozole as extended adjuvant therapy post tamoxifen. Results from this study suggests that letrozole does not significantly alter serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides or Lp(a) in non-hyperlidiemic postmenopausal women with primary breast cancer treated up to 36 months following at least 5 years of adjuvant tamoxifen therapy. These findings further support the tolerability of extended adjuvant letrozole in postmenopausal women following standard tamoxifen therapy.",
keywords = "Letrozole, Postmenopausal women, Primary breast cancer, Serum lipids, Tamoxifen",
author = "Wasan, {K. M.} and Goss, {P. E.} and Pritchard, {P. H.} and L. Shepherd and Palmer, {M. J.} and S. Liu and D. Tu and Ingle, {J. N.} and M. Heath and D. DeAngelis and Perez, {E. A.}",
year = "2005",
month = "5",
doi = "10.1093/annonc/mdi158",
language = "English (US)",
volume = "16",
pages = "707--715",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)

AU - Wasan, K. M.

AU - Goss, P. E.

AU - Pritchard, P. H.

AU - Shepherd, L.

AU - Palmer, M. J.

AU - Liu, S.

AU - Tu, D.

AU - Ingle, J. N.

AU - Heath, M.

AU - DeAngelis, D.

AU - Perez, E. A.

PY - 2005/5

Y1 - 2005/5

N2 - Background: The purpose of this study was to evaluate changes in serum lipid parameters {cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein(a) [Lp(a)]}, in postmenopausal women receiving letrozole or placebo after adjuvant tamoxifen for early stage breast cancer (NCIC CTG MA.17L). Patients and methods: MA.17L is a substudy of MA.17, a randomized, double-blind, placebo-controlled trial of letrozole 2.5 mg taken daily for 5 years in postmenopausal women with primary breast cancer completing ∼5 years of prior adjuvant tamoxifen. Patients consenting to participate in this companion study had blood drawn and lipid parameters (total cholesterol, HDL cholesterol, LDL cholesterol, Lp(a), triglycerides) evaluated at baseline, 6 months, 12 months and yearly thereafter until completion of protocol therapy. It was required that women be non-hyperlipidemic and not taking lipid-lowering drugs at time of entry on this trial. Results: Three hundred and forty seven women were enrolled in the study. The letrozole and the placebo groups demonstrated marginally significant differences in the percentage change from baseline in HDL cholesterol at 6 months (P = 0.049), in LDL cholesterol at 12 months (P = 0.033) and triglycerides at 24 months (P = 0.036). All comparisons of lipid parameters at other time points were not significantly different between the two treatment groups. No statistically significant differences in the number of patients exceeding the thresholds defined for the lipid parameters were found between the two treatment groups. Conclusions: The MA.17 trial demonstrated a significant improvement in disease-free survival with the use of letrozole as extended adjuvant therapy post tamoxifen. Results from this study suggests that letrozole does not significantly alter serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides or Lp(a) in non-hyperlidiemic postmenopausal women with primary breast cancer treated up to 36 months following at least 5 years of adjuvant tamoxifen therapy. These findings further support the tolerability of extended adjuvant letrozole in postmenopausal women following standard tamoxifen therapy.

AB - Background: The purpose of this study was to evaluate changes in serum lipid parameters {cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein(a) [Lp(a)]}, in postmenopausal women receiving letrozole or placebo after adjuvant tamoxifen for early stage breast cancer (NCIC CTG MA.17L). Patients and methods: MA.17L is a substudy of MA.17, a randomized, double-blind, placebo-controlled trial of letrozole 2.5 mg taken daily for 5 years in postmenopausal women with primary breast cancer completing ∼5 years of prior adjuvant tamoxifen. Patients consenting to participate in this companion study had blood drawn and lipid parameters (total cholesterol, HDL cholesterol, LDL cholesterol, Lp(a), triglycerides) evaluated at baseline, 6 months, 12 months and yearly thereafter until completion of protocol therapy. It was required that women be non-hyperlipidemic and not taking lipid-lowering drugs at time of entry on this trial. Results: Three hundred and forty seven women were enrolled in the study. The letrozole and the placebo groups demonstrated marginally significant differences in the percentage change from baseline in HDL cholesterol at 6 months (P = 0.049), in LDL cholesterol at 12 months (P = 0.033) and triglycerides at 24 months (P = 0.036). All comparisons of lipid parameters at other time points were not significantly different between the two treatment groups. No statistically significant differences in the number of patients exceeding the thresholds defined for the lipid parameters were found between the two treatment groups. Conclusions: The MA.17 trial demonstrated a significant improvement in disease-free survival with the use of letrozole as extended adjuvant therapy post tamoxifen. Results from this study suggests that letrozole does not significantly alter serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides or Lp(a) in non-hyperlidiemic postmenopausal women with primary breast cancer treated up to 36 months following at least 5 years of adjuvant tamoxifen therapy. These findings further support the tolerability of extended adjuvant letrozole in postmenopausal women following standard tamoxifen therapy.

KW - Letrozole

KW - Postmenopausal women

KW - Primary breast cancer

KW - Serum lipids

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=20044380552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044380552&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi158

DO - 10.1093/annonc/mdi158

M3 - Article

C2 - 15817595

AN - SCOPUS:20044380552

VL - 16

SP - 707

EP - 715

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -